Blue Note Pharmaceuticals is a privately held biopharmaceutical company with offices in Troy,
New York and Amsterdam, The Netherlands. Blue Note's mission is to acquire, advance, develop, partner and commercialize carefully selected undervalued drug development candidates with the potential to more effectively treat or help prevent major medical conditions affecting society. The Company's lead development project is BNP 32,762, a pharmacokinetically unique calcium channel blocker (CCB) being evaluated in late-stage clinical trials for the treatment of hypertension and chronic stable angina.

Blue Note is also evaluating various products that would combine BNP 32,762 with other commonly accepted antihypertensive drugs such as ACE inhibitors, Angiotensin Receptor Blockers (ARBs) and diuretics.

The Company's cardiovascular-oriented pipeline also includes an early-stage program for the prevention of Deep Vein Thrombosis (DVT) and for the treatment of a number of other important cardiovascular indications.